IMAPAC’s Post

Join our insightful webinar where Dr. Amarnath Chatterjee will provide updates on host impurities in biologics, focusing on regulatory requirements from a safety perspective. Register now https://lnkd.in/gzqZbCte #biopharma #regulatorycompliance #impurities #HostCellProteins Ankush Sharma; Vadiraja Bhat, PhD.; Ashish Pargaonkar

Over the past 10 years, Paras Biopharmaceuticals Finland has actively engaged in and provided services to campaigns across the USA and Europe. We are well aware of the challenges posed by funding, time constraints, and quality requirements. Therefore, Paras Biopharmaceuticals is launching a campaign on “Faster Turnaround Times for 2024 / 2025 batches for Scale-up Development & Production.” We are eager to learn about your projects and assist in the development of scale-up batches for your critical ‘next steps,’ including Materials for Studies on IND Filing & Tox Materials. Quality of Biologics will remain a priority, even with “Faster Turnaround Times.” Paras Biopharmaceuticals’ contributions to your projects include affordable health solutions, quality, and productivity. #cdmo #biosimilars #technologies

Over the past 10 years, Paras Biopharmaceuticals Finland has actively engaged in and provided services to campaigns across the USA and Europe. We are well aware of the challenges posed by funding, time constraints, and quality requirements. Therefore, Paras Biopharmaceuticals is launching a campaign on “Faster Turnaround Times for 2024 / 2025 batches for Scale-up Development & Production.” We are eager to learn about your projects and assist in the development of scale-up batches for your critical ‘next steps,’ including Materials for Studies on IND Filing & Tox Materials. Quality of Biologics will remain a priority, even with “Faster Turnaround Times.” Paras Biopharmaceuticals’ contributions to your projects include affordable health solutions, quality, and productivity. #cdmo #biosimilars #technologies

LAST CHANCE to submit your topics and presentations for the 2024 ASAP BioPharma Conference! The conference will be held in Boston from November 4-6, 2024. We need your expertise and thought-leadership to ensure the most valuable and current topics regarding partnering, collaboration, and alliance management in the biopharma and life sciences industries are addressed. Don't miss this opportunity to contribute your knowledge! Submit your topics before the deadline on Friday, May 3, 2024 at https://lnkd.in/ehXhGm7U. #alliancemanagement #alliances #strategicalliances #alliancemanagers #collaboration #strategicpartnerships #pharmaceutical #pharmaceuticalindustry #biopharma #biotech #biotechnology #biotechindustry

As a CDMO, it's crucial to direct your marketing efforts toward the right decision makers in biotech and pharma companies. Directors of Biologics, VPs of Production, and Heads of Manufacturing are some of the roles that drive CDMO selection at biotech and pharma companies. But how do you create content that speaks to their priorities with credible proof points that differentiate your service and build trust with potential clients? Find out what they’re looking for in the latest article from Samba: https://hubs.li/Q02F6zNF0 #BiotechMarketing #LifeScienceMarketing #CDMO #Pharma #TacticalMarketing

Over the past 10 years, Paras Biopharmaceuticals Finland has actively engaged in and provided services to campaigns across the USA and Europe. We are well aware of the challenges posed by funding, time constraints, and quality requirements. Therefore, Paras Biopharmaceuticals is launching a campaign on “Faster Turnaround Times for 2024 / 2025 batches for Scale-up Development & Production.” We are eager to learn about your projects and assist in the development of scale-up batches for your critical ‘next steps,’ including Materials for Studies on IND Filing & Tox Materials. Quality of Biologics will remain a priority, even with “Faster Turnaround Times.” Paras Biopharmaceuticals’ contributions to your projects include affordable health solutions, quality, and productivity. #cdmo #biosimilars #technologies

📢 Boost Your Drug Development with Thermo Fisher's Accelerator! 🌟 Thermo Fisher Scientific has launched Accelerator™ Drug Development. This suite expands their CRO and CDMO services. ⚙️ It offers customizable support for biotech and pharma companies at every drug development stage. 📈 The aim is to enhance efficiency, save costs, and improve clinical outcomes. 🤝 Leveraging expertise from past acquisitions, this launch responds to increasing industry consolidation. #BioprocessUpdates #ThermoFisher #Accelerator #DrugDevelopment #CRO #CDMO #Biotech #Pharma #ClinicalOutcomes #Efficiency #CostSavings #IndustryConsolidation #LifeSciences #Pharmaceuticals #Innovation #Healthcare ▷ Read the full article here: 📎 https://lnkd.in/dduKEKvj

Over the past 10 years, Paras Biopharmaceuticals Finland has actively engaged in and provided services to campaigns across the USA and Europe. We are well aware of the challenges posed by funding, time constraints, and quality requirements. Therefore, Paras Biopharmaceuticals is launching a campaign on “Faster Turnaround Times for 2024 / 2025 batches for Scale-up Development & Production.” We are eager to learn about your projects and assist in the development of scale-up batches for your critical ‘next steps,’ including Materials for Studies on IND Filing & Tox Materials. Quality of Biologics will remain a priority, even with “Faster Turnaround Times.” Paras Biopharmaceuticals’ contributions to your projects include affordable health solutions, quality, and productivity. #cdmo #biosimilars #technologies

Article in Nature Magazine Review and Drug Discovery presents an analysis of global R&D investment and revenue in 2021 for the full range of companies in the biopharmaceutical ecosystem — public and private companies, at the development stage and commercial stage — using reported financial statement data and data on capital raises. Trends on the spend from big players is on the rise albeit caveats that the data are stopping at 2021 (which includes COVID but not the post-COVID). The authors noted the role of Gov funding in provision of basic science. However I think the Gov funding are doing substantially more despite not showing this research. Side note, Canada is bundled with "other" even in the supp. data. which makes it impossible to look. Same for EU countries all bundle in one. Always sad to lose data in a study 😕 #investment #Researchanddevelopment #biopharma #ROI https://lnkd.in/ei2WNEpk).

⭐Did you know that successful technology transfer in biologics manufacturing can save time, resources, and potentially impact patient safety? Syngene International, a leading global CRDMO, has developed a unique '100% first time right' approach to technology transfer in biologics manufacturing. This innovative method involves: •A risk-based assessment of incoming data •Using Decision Trees to evaluate confidence levels in processes and analytical methods •Creating detailed Technology Transfer approach documents The result? A track record of consistent yields and successful transfers, regardless of differences in infrastructure, equipment, or processes between sites. Want to learn more about achieving biologics manufacturing milestones through effective technology transfer? Read the full viewpoint in the link provided in comments section! 🔗 #BiologicsManufacturing #TechnologyTransfer #Pharma #Biotechnology #CRDMO